作者
Yu Nakanishi, Takeshi Masuda, Kakuhiro Yamaguchi, Shinjiro Sakamoto, Yasushi Horimasu, Taku Nakashima, Shintaro Miyamoto, Yasuhiro Tsutani, Hiroshi Iwamoto, Kazunori Fujitaka, Yoshihiro Miyata, Hironobu Hamada, Morihito Okada, Noboru Hattori
发表日期
2019/9/1
期刊
Respiratory Investigation
卷号
57
期号
5
页码范围
451-459
出版商
Elsevier
简介
Background
Approximately 5% of non-small cell lung cancer (NSCLC) patients develop immune checkpoint inhibitor (ICI)-induced interstitial lung disease (ICI-ILD), 10% of whom die. However, there are no established risk factors for its occurrence. Interstitial lung abnormalities (ILA) are areas of increased lung density on lung computed tomography (CT) in individuals with no known ILD. This study retrospectively investigated whether any patient characteristics, including ILA, were risk factors for ICI-ILD in patients with NSCLC.
Methods
NSCLC patients who received anti-programmed death (PD)-1 antibody treatment at our hospital between September 2015 and December 2017 were enrolled. Information on patient characteristics before anti-PD-1 antibody administration, including chest CT findings and laboratory data, were obtained.
Results
Among 83 enrolled patients, the incidence of ICI-ILD was 16.9% (14/83). All …
学术搜索中的文章
Y Nakanishi, T Masuda, K Yamaguchi, S Sakamoto… - Respiratory Investigation, 2019